KING STAR CAPITAL
King Star Capital is a U.S. dollar fund managed by Kington Capital. The first phase of the fund focuses on innovative biopharmaceutical companies in China. It has invested in leading anti-tumor biopharmaceutical R&D enterprises including CStone Pharmaceuticals, MabSpace Biosciences, JW Therapeutics and Adagene Pharmaceutical.
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2020-10-28 | Gracell Biotechnologies | King Star Capital investment in Series C - Gracell Biotechnologies | 100 M USD |
| 2019-02-25 | Gracell Biotechnologies | King Star Capital investment in Series B - Gracell Biotechnologies | 85 M USD |
| 2018-05-11 | MabSpace Biosciences | King Star Capital investment in Series B - MabSpace Biosciences | 40 M USD |
| 2018-05-09 | CStone Pharmaceuticals | King Star Capital investment in Series B - CStone Pharmaceuticals | 260 M USD |
| 2018-03-27 | Adagene | King Star Capital investment in Series C - Adagene | 50 M USD |